Publicaciones en colaboración con investigadores/as de Netherlands Cancer Institute (12)

2022

  1. The impact of COVID-19 on oncology professionals—one year on: lessons learned from the ESMO Resilience Task Force survey series

    ESMO Open, Vol. 7, Núm. 1

2021

  1. Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies

    ESMO Open, Vol. 6, Núm. 6

  2. Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey

    ESMO Open, Vol. 6, Núm. 3, pp. 1-7

  3. The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II

    ESMO open, Vol. 6, Núm. 4, pp. 100199

  4. The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration

    ESMO open, Vol. 6, Núm. 2, pp. 100058

2020

  1. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

    Annals of Oncology, Vol. 31, Núm. 10, pp. 1320-1335

  2. Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts

    Radiotherapy and Oncology, Vol. 149, pp. 84-88

2019

  1. Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts

    Radiotherapy and Oncology, Vol. 135, pp. 74-77

  2. Erratum to “Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts” [Radiother. Oncol. 135 (2019) 74–77](S0167814019300775)(10.1016/j.radonc.2019.02.010)

    Radiotherapy and Oncology

  3. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the committee for medicinal products for human use (chmp)

    Annals of Oncology

  4. Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts

    Radiotherapy and Oncology, Vol. 133, pp. 163-166

2017

  1. Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: The SELECT-1 randomized clinical trial

    JAMA - Journal of the American Medical Association, Vol. 317, Núm. 18, pp. 1844-1853